Search
Nelutroctiv
go.drugbank.com/drugs/DB21554InvestigationalNelutroctiv is under investigation in clinical trial NCT05662215 (A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants).
Almonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigational[A231864] Almonertinib was also approved by the EMA on February 20, 2026.[L56068]
AZD2315
go.drugbank.com/drugs/DB06540ExperimentalThe drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase
Colistin
go.drugbank.com/drugs/DB00803ApprovedInvestigationalColistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.
Dostarlimab
go.drugbank.com/drugs/DB15627ApprovedInvestigational[L33320] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the … In April 2021, dostarlimab was granted accelerated approval by the FDA - as GlaxoSmithKline's dostarlimab-gxly (Jemperli) - for the treatment of adult patients with recurrent or advanced mismatch repair
Hydromorphone
go.drugbank.com/drugs/DB00327ApprovedIllicitInvestigational[A176495] The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984.[L5795]
Ursodeoxycholic acid
go.drugbank.com/drugs/DB01586ApprovedInvestigational[A256272] UDCA works by replacing the hydrophobic or more toxic bile acids from the bile acid pool.[A256272] … [A256272] UDCA was first approved by the FDA in 1987 for dissolution of gallstones and for primary biliary cirrhosis in 1996.
Forigerimod
go.drugbank.com/drugs/DB12490InvestigationalForigerimod is under investigation for the treatment of Lupus Erythematosus, Systemic.
Categories: Ribonucleoprotein, U1 Small NuclearMifepristone
go.drugbank.com/drugs/DB00834ApprovedInvestigationalIts inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua.
Glofitamab
go.drugbank.com/drugs/DB16371ApprovedInvestigationalIt has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells. … [L45698,A258488] Glofitamab was approved by Health Canada in March 2023 for the treatment of certain patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), becoming the first CD20